New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England.

ABSTRACT: New direct-acting antivirals have the potential to transform the hepatitis C (HCV) treatment landscape, with rates of sustained viral response in excess of 90%. As these new agents are expensive, an important question is whether to focus on minimizing the consequences of severe liver disease, or reducing transmission via 'treatment as prevention'. A back-calculation model was used to estimate the impact of treatment of mild, moderate and compensated cirrhosis on incident cases of HCV-related end-stage liver disease/hepatocellular carcinoma (ESLD/HCC). In addition, a dynamic model was used to determine the impact on incidence and prevalence of chronic infection in people who inject drugs (PWID), the main risk group in England. Treating 3500 cirrhotics per year was predicted to reduce ESLD/H

SUBMITTER: Harris RJ 

PROVIDER: S-EPMC4982023 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature